NCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
H. Lee Moffitt Cancer Center and Research Institute
Duke University
Cancer Research UK
Tongji Hospital
Tianjin Medical University Cancer Institute and Hospital
WiSP Wissenschaftlicher Service Pharma GmbH
King Faisal Specialist Hospital & Research Center
Medical University of Gdansk